Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Platinum-Resistance Among Women with Ovarian Cancer

Gynecol Oncol; ePub 2016 May 25; Slaughter, Holman, et al

Primary (PPR) and acquired (APR) platinum-resistant patients have a poor prognosis and overall survival (OS) is related to the number of biologic agents received. This according to a study of 330 patients with high grade serous ovarian cancer between 2000 and 2010. Researchers found:

• 81 (25%) patients had PPR; of the remaining women, 55 (22%) developed APR.

• Median progression free survival (PFS) of PPR patients was 4.2 months and median OS was 17.8 months.

• Patients with APR had a median PFS of 14.2 months and a median OS of 56 months.

• OS from the date of platinum resistance was 21.9 months.

• Multivariate analysis found cancer stage and clinical trial participation to be associated with OS.

Citation: Slaughter K, Holman LL, Thomas EL, et al. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. [Published online ahead of print May 25, 2016]. Gynecol Oncol. doi:http://dx.doi.org/10.1016/j.ygyno.2016.05.020.